5-Cyclopropyl-3-methyl-4-propan-2-yl-1,2-oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Cyclopropyl-3-methyl-4-propan-2-yl-1,2-oxazole
• 英文别名: 5-cyclopropyl-3-methyl-4-propan-2-yl-1,2-oxazole
• 化学式: C₁₀H₁₅NO
• 分子量: 165.23
• InChiKey: SRVWESBZMWMXHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array Biopharma, Inc.

  公开号：EP3849986B1

  公开（公告）日：2022-06-08
• US20140256706A1
  申请人：——

  公开号：US20140256706A1

  公开（公告）日：2014-09-11
• BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20170281773A1

  公开（公告）日：2017-10-05

  Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.
• US9675697B2
  申请人：——

  公开号：US9675697B2

  公开（公告）日：2017-06-13
• [EN] FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS COMME INHIBITEURS DE KINASES RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020055672A1

  公开（公告）日：2020-03-19

  Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein Rx, Ry, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.